Marco Donia
@DoniaMarco
Followers
595
Following
204
Media
43
Statuses
308
Clinician-Scientist Oncologist @CCITdk , Assoc. Prof. @uni_copenhagen , #immunotherapy #melanoma #RWE #TIL #cancer . Web:
Copenaghen, Danimarca
Joined June 2018
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
España
• 463075 Tweets
Kroos
• 463002 Tweets
Project 2025
• 377468 Tweets
Spain
• 339928 Tweets
Portugal
• 317401 Tweets
Mbappe
• 225507 Tweets
Alemania
• 189269 Tweets
Nico
• 165569 Tweets
Lamine
• 159442 Tweets
Pedri
• 156556 Tweets
Wisconsin
• 114136 Tweets
#ESPGER
• 107824 Tweets
المانيا
• 85554 Tweets
Carvajal
• 84437 Tweets
Almanya
• 80231 Tweets
Havertz
• 77510 Tweets
Morata
• 72489 Tweets
Wirtz
• 66854 Tweets
Cucurella
• 62328 Tweets
Musiala
• 59182 Tweets
Merino
• 51602 Tweets
Dani Olmo
• 47888 Tweets
スペイン
• 44561 Tweets
Rodri
• 43654 Tweets
#PORFRA
• 42866 Tweets
Anthony Taylor
• 40598 Tweets
De la Fuente
• 33644 Tweets
Ferran
• 33269 Tweets
#GERESP
• 25476 Tweets
#Eurocopa2024
• 25226 Tweets
كروس
• 24242 Tweets
Spanien
• 22129 Tweets
Leao
• 21256 Tweets
Rudiger
• 20327 Tweets
クロース
• 18057 Tweets
Joselu
• 16293 Tweets
Fullkrug
• 16083 Tweets
Oyarzabal
• 14398 Tweets
#FRAPOR
• 13419 Tweets
ポルトガル
• 12112 Tweets
Genetic immune escape mechanisms found in 25% of
#Cancers
. HLA-I alterations primarily in high
#TMB
cancers. Important findings for tailored
#Immunotherapy
Thanks
@fran_mj88
for sharing a great work on
@NatureGenet
0
29
78
🌟 Did you know CD4+ T cells can kill
#immunotherapy
-resistant
#cancer
?
👉 published by
@CCR_AACR
🎯 We revealed a new approach that may overcome some immune checkpoint blockade (ICB)-resistant tumors by harnessing CD4+ T cells
#TILs
#Melanoma
3
19
46
All you need to know about Evidence in Cancer Immunotherapy. Now online, free at
Thanks to the outstanding speakers
@VPrasadMDMPH
and
@Alfdoc2
, to
@CCITdk
@HerlevGentofte
, and
@koebenhavns_uni
to make this happen!
3
14
37
Neo-adjuvant
#Immunotherapy
in macroscopic, resectable
#melanoma
: pathological responses predict long-term clinical outcomes
▶ Patients with ≤10% viable tumor after neo-adjuvant had a 5-year OS of 100%
Small study, to date longest FU in neo-adjuvant
0
9
33
Cell therapy with tumor-infiltrating lymphocytes (
#TILs
): a safe, feasible and effective treatment modality for selected patients with metastatic
#melanoma
📚 The past, present, and future of TIL therapy reviewed in
@CCR_AACR
👉 👈
#TIL
#celltherapy
2
13
35
It was a great honor to be awarded the 2019
@lundbeckfonden
Fellowship, in good company of 9 excellent scientists. Looking forward to kickstart this exciting
#immunotherapy
research project at
@CCITdk
in collaboration with
@jonsson_lab
. Learn more at
3
4
30
The real-world value of anti-PD-1 in patients with metastatic melanoma from an entire country
✅ Sustained OS benefit >5 years after the introduction of anti-PD-1.
✅ Improved survival, regardless of eligibility to clinical trials
👉 (Eur J Cancer)
2
8
32
#Melanoma
at
#ESMO23
:
Promising early results of TIL
#celltherapy
in Mucosal melanoma.
ORR 50%, durable responses. Is TIL as effective as in cutaneous melanoma?
@myESMO
#melsm
0
8
30
Important piece of work describing why current ways to assess PFS are suboptimal, and rarely correlate well with outcomes that matter: OS and QoL.
Still waiting to see the relation between RFS and OS in
#adjuvant
anti-PD-1
#immunotherapy
for
#melanoma
2
3
28
Therapy with
#TILs
in
#melanoma
at
#ESMOImmuno23
1️⃣ Heavily-pretreated: 4-yr OS 22%
2️⃣ Complete metabolic response predicts long-term survival
3️⃣ TILs plus oncolytic virus (armed with TNF and IL-2)
4️⃣ TILs plus nivolumab in anti-PD-1 refractory
More at
2
13
33
**
#PDL1
status in metastatic
#melanoma
**
-
@EMA_News
approved
#Opdualag
(
#relatlimab
plus
#nivolumab
) only for patients whose tumors express low PD-L1
-
@US_FDA
approved regardless of PD-L1
more at
2
9
25
Uveal melanoma, an unmet medical need
👁️Rare melanoma originating from the eye
💊Only Tebentafusp - largely unavailable in many countries incl.🇩🇰 - shown randomized survival improvement
Excellent review from
@TurajlicLab
& coll.
#uvealmelanoma
#eyecancer
👇👇👇👇👇👇👇👇👇
🔖 Latest REVIEW by
@CamilleGrard6
,
@Ben_Shum_
,
@pdnpdnpdn
&
@SamraTurajlic_
@TurajlicLab
.
Immuno-oncology approaches in uveal melanoma: tebentafusp & beyond...
#OpenAccess
👇
2
12
22
0
3
26
Great listening to the inspiring talk of
@VPrasadMDMPH
and learn how to make better use of
#denmark
's platforms for real-world evidence
#rwe
Great to be in Denmark to talk about the strengths and limitations of Real World Evidence
I will post the audio to
@Plenary_Session
and the slides to
Has been nice to give talks across 3 countries this week
10
11
117
1
1
23
~30% of patients with response experience acquired resistance to
#immunotherapy
(ARI) in
#melanoma
New data shed light on patterns of ARI (largely oligometastatic), and outcomes of salvage treatment
0
9
27
❄Cold tumors: T cell exclusion and/or T cell desertification
🔥 Make Tumors Hot Again
👉 (Reviewed in the
@BrJCancer
)
✔ Check the 16 known mechanisms leading to T cell exclusion or T cell desertification in one single table
0
2
22
Honoured to be part of this group. I will be sharing content primarily on
#melanoma
and
#immunotherapy
during
#ESMO23
1
2
22
1
10
21
@myESMO
supports
#WNTD23
: tobacco growing & production lead to global ecological harm,
#ClimateChange
& more
#CancerPatients
.
We need anything but tobacco‼️
0
6
16
**Acquired resistance to
#melanoma
Immunotherapy**
Approx. 30% of patients with
#melanoma
who initially respond to
#Immunotherapy
later progress. Knowledge of molecular mechanisms helps develop new treatments for this major challenge in
#oncology
Check out how
#melanoma
acquires resistance to multiple lines of
#immunotherapy
by gaining consecutive alterations, resulting in pan T-cell immune escape. By Nielsen,
@MarioPre_
, Svane,
@DoniaMarco
et al.
@AriannaDraghi
@CAChamberlain_
@Michael44364760
0
4
18
0
7
21
A 8+ years journey bringing the first results. This is great news for patients and for science. Great work of the previous and current members of the TIL teams at
@CCITdk
and
@NKI_nl
@NKI_nl
and
@CCITdk
announce TIL
#celltherapy
meets the primary endpoint of progression-free survival in
#melanoma
in a randomized phase 3 trial. Full press release at
0
1
7
1
3
20
In this interesting editorial on
@BrJCancer
, G. Long and colleagues discuss our recent paper on T cell responses in
#immunotherapy
resistant
#melanoma
. We should explore the mechanisms of immune resistance in immunologically "hot" tumors
0
11
20
2
4
19
1
4
19
#ESMO23
takeaway for
#melanoma
:
1⃣ Promising advancements in rare subtypes (uveal
#UVM
and mucosal)
2⃣ Early results from personalized therapies (vaccines and
#CellTherapy
)
3⃣ Confirming frontline
#immunotherapy
better for most patients
@myESMO
2
9
18
Great presentation by
@ajsfurness
at
#ESMOImmuno21
discussing how preclinical biomarkers can affect clinical development in
#Immunotherapy
@myESMO
0
7
17
Some - but still very few - patients with
#melanoma
and symptomatic brain metastases may derive significanr benefit from combination
#Immunotherapy
, according to a retrospective analysis. Prospective results needed.
@ajsfurness
0
3
17
Exciting program at the "Solid Tumour Cell Therapy Preceptorship" in London, Oct 11th 2023
Register at
Come join us at the Solid Tumour Cellular Therapy Preceptorship on 11 October! 💉All multidisciplines welcome!
Talks by
@ajsfurness
@drclaireroddie
@DrBetofMDPhD
@DoniaMarco
0
3
7
0
4
17
Most combinations in oncology have additive but not synergistic efficacy.
💡 if A+B (combo) better than A alone or B alone because of additive PFS, A-->B (sequencing at progression) may very well be as good as A+B
❓ Is toxicity additive or synergistic
@ac_palmer
@HaeunHwangbo
⭐️ONLINE NOW
@NatureCancer
- “Additivity predicts the efficacy of most approved combination therapies for advanced cancer” by
@ac_palmer
& Co.
Read it here 👇
0
8
28
2
5
18
In this study, our team
@PennCancer
found that pseudoprogression is very rare in NSCLC. Keeping pts on CPI past PD hoping for it to occur could be dangerous
@CharuAggarwalMD
3
19
33
0
1
15
@myESMO
Take home messages from
#ESMO23
for
#melanoma
1⃣ Promising advancements in rare subtypes (uveal
#UVM
and mucosal)
2⃣ Early results from personalized therapies (vaccines and
#CellTherapy
)
3⃣ Confirming frontline
#immunotherapy
better for most patients
0
7
17
A super interesting meeting on
#celltherapy
organized by
@ajsfurness
and
@drclaireroddie
, honoured to have joined as international speaker together with
@DrBetofMDPhD
and learnt about the
#celltherapy
programs flourishing across the UK.
0
3
16
We are beginning to decipher the role of B cell receptor diversity in
#cancer
and
#Immunotherapy
. Check the article below if you want to know more
Funding by
@SSTSundhed
,
@lundbeckfonden
and
@HerlevGentofte
. Collaboration with
@jonsson_lab
and
@cancer_dk
research center
New
#JITC
article: Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
@jonsson_lab
@DoniaMarco
0
6
19
0
6
16
Exciting works ahead
The fast-paced
#oncology
environment poses new challenges for
#CancerCommunication
: thanks to the members of the new ESMO
#CommunicationCommittee
for your active and enthusiastic participation in the first workshop. Stay tuned!
2
12
48
0
1
16
It will be again my pleasure to post about the main findings at
#ESMOImmuno23
here and on LinkedIn
‼️Stay tuned
#ESMOImmuno23
: Stay abreast of the latest
#ScientificFindings
in
#ImmunoOncology
thanks to the
#ExpertInsights
brought to you by the ESMO Social Media Ambassadors. Keep an eye on these accounts & become part of the conversation.
📌
2
13
21
0
3
17
#ESMOImmuno23
Immunotherapy+Targeted therapy in NSCLC so far according to
@DrJNaidoo
👉Modest activity of PD1+targeted therapy
👉 Synergistic toxicity
@myESMO
0
6
17
Better 6 month PFS and higher ORR with ipi+nivo vs ipi in PD-1 resistant
#Melanoma
. However, still no real answer on outcomes that matter (OS and QoL), and no better mPFS. Overall, very poor outcomes in this patient population (OS much <2 yrs), desperate need for better options
1
1
15
One of the best slides ever seen in an ESMO event. Great
@E_de_Azambuja
#LGP18
@E_de_Azambuja
@Tony_Calles
@myESMO
@g_mountzios
@VanBran44
@KFumasoli
You didn’t stop us…
@Alfdoc2
@DoniaMarco
1
0
7
2
1
16
If you are a
#ukrainian
🇺🇦 scientist with interest in
#cancer
research or
#oncologist
, please feel free to contact me if you need any kind of support e.g. getting in touch with labs or hospitals in Denmark🇩🇰 or other
#ScienceForUkraine
@Sci_for_Ukraine
@CCITdk
can host displaced
#ukrainian
🇺🇦scientists with interest in
#cancer
#immunotherapy
. Get in touch to explore possibilities via
#ScienceForUkraine
@Sci_for_Ukraine
0
5
10
0
1
13
Stay tuned,
#ESMO23
kick-off in two days!
#ESMO23
: Do not miss the insights on the latest
#OncologyResearch
brought to you by the ESMO Social Media Ambassadors. Stay abreast of the latest scientific findings and join the conversation.
📌
2
22
82
0
1
13
@AriannaDraghi
presenting her
#Immunotherapy
works on how to identify tumor-reactive T cells from at
#esmoimmuno19
@myESMO
. Thanks
@cancer_dk
,
@lundbeckfonden
and
@HerlevGentofte
for support!
2
6
13
While awaiting the OS results of Keynote-054 on Pembro vs placebo, this retrospective study begins questioning the current standard practice on
#adjuvant
therapy offered to patients with stage III resected
#Melanoma
No OS benefit seen after the introduction of adjuvant treatment in stage III melanoma in Sweden.
Check out our just published JNCI paper!
@OlofssonBagge
@ny_lars
4
4
24
2
1
12
Tebentafusp (Kimmtrak) *NOT* reimbursed in Denmark 🇩🇰 for treating patients with
#ocularmelanoma
👉
What is the status in other countries?
#uvealmelanoma
#melanoma
#melsm
8
4
12
Exciting data from
#ASCO23
on personalized
#cancer
#vaccines
in
#melanoma
. Caution is however needed, short follow up (>80 weeks landmark with less than 29 pts at risk in the control group), graphs below 👇
0
3
12
@GiorgiaMeloni
@FratellidItalia
Wow, I guess the "clinical evidence" you are referring to is reported in Meloni et al. 2021, published in the
@NEJM
?
2
2
10
Prophylactic
#immunotherapy
is moving forward
A new generation of cancer-preventing vaccines could wipe out tumors before they form.
Learn more:
@NewsfromScience
17
195
687
0
3
10
@alexshoushtari
Why does FDA/EMA not mandate OS analysis , 7+ years after last patient randomised in KN-054, even if "insufficient statistical power"? It is public interest
2
0
9
TILs following progression to
#antipd1
are functional and can mediate responses!
#Immunotherapy
#immunooncology
#melsm
#melanoma
0
7
9
Improving the management of
#melanoma
by sharing clinical care and research experiences with
@PoschChristian
#samarbejdeomkr
æft at
@HerlevGentofte
#dksund
#dkforsk
@DCCCcancer
thanks to
@cancer_dk
0
1
9
How to treat BRAF WT
#melanoma
following progression on single agent
#antiPD1
? Very actual to predict responses to
#antiCTLA4
, huge need of knowledge in
#immunotherapy
for
#melanoma
#melsm
congrats
@ajsfurness
Congrats to my friend
@ajsfurness
for his presentation in
#Paris
at the
#MAP
. So sorry I missed it but I hope to see it soon through
#ESMO
website.
0
1
9
0
4
9
#melanoma
at
#ESMO23
:
New data confirm frontline
#Immunotherapy
better for most patients with BRAF+ disease, even with high LDH
@myESMO
#melsm
0
2
9
@gbanna74
@JAMAOnc
@OncoAlert
@OncoViews
In
#melanoma
, retrospective data indicated that PET scans can identify patients with an excellent prognosis despite (much) earlier discontinuation. Any similar studies in
#lungcancer
?
1
2
8
As I understand from the answers:
DK *no*
SE *no*
NO *no*
PL *no*
NZ *no*
AU *no*
Interesting to know more about additional countries
4
0
8
Keynote presentation by a true
#immunotherapy
pioneer
@carlhjune
at
#ESMOimmuno19
. Spectacular successes in hematological, less in solid
#Cancers
. The best is yet to come
@myESMO
0
2
6
Frequent toxicities following rechallenge with
#antiPD1
after severe
#irAEs
to antiCTLA4+PD1. However, many patients, tolerated anti-PD-1 rechallenge well
#melsm
#melanoma
#Immunotherapy
0
0
6
The recent introduction of new systemic treatments for
#melanoma
had a positive impact on the whole population of patients diagnosed with this disease in
#Denmark
. However, only a small impact on patients with the worst prognosis
#melsm
#Immunotherapy
#dkforsk
What is the real impact of modern treatments on the survival of patients with metastatic
#melanoma
? Survival definitely better in recent years, but still a lot to improve
#melsm
#immunotherapy
#dkforsk
@DoniaMarco
@EORTC
0
3
9
1
1
6
In this manuscript, we review the current knowledge on
#AcquiredResistance
to cancer
#immunotherapy
1
1
6
@Timothee_MD
Thank you, it has been a great pleasure and honor to organize this event and bring such outstanding speakers at
@CCITdk
@HerlevGentofte
!
0
1
6
Here we have shown that the introduction of new treatments, such as
#Immunotherapy
, had a real impact on
#Melanoma
survival regardless of patient eligibility to clinical trials
#melsm
#dkforsk
What is the real impact of modern treatments on the survival of patients with metastatic
#melanoma
? Survival definitely better in recent years, but still a lot to improve
#melsm
#immunotherapy
#dkforsk
@DoniaMarco
@EORTC
0
3
9
0
2
6
This will be an exciting meeting. Outstanding speakers will discuss how to improve the treatment of
#melanoma
#melsm
Don’t forget to register to the Nordic melanoma meeting in Copenhagen Sept 5-7! Abstract deadline July 8. Invited speakers from USA
@JeffGershenwald
Netherlands Germany Australia UK Sweden and Denmark
#melanoma
#conference
3
6
14
2
2
5
0
0
2
0
1
7
Still some days left to apply for this exciting position!
New
#research
position available in
@DoniaMarco
's team at
@CCITdk
. If you are a bioinformatician with interest in
#immunotherapy
and
#rnaseq
, do not hesitate to apply! PhD required
#joboffer
#sciencejobs
#bioinformatics
#postdoc
0
7
11
1
2
6
@MdCurioni
@myESMO
Thank you
@MdCurioni
, exciting panel discussions on how immunological memory influences
#immunotherapy
with you and
@ajsfurness
. Webcasts soon available at
0
2
5
Open access at
Still unclear what is the optimal treatment duration for patients with metastatic
#melanoma
, however this real-world study shows that a negative PET scan can support decision for
#immunotherapy
discontinuation. Support by
@SSTSundhed
@HerlevGentofte
#RWE
#MELSM
#dkforsk
1
1
5
0
0
4
@Hildur10016016
@OlofssonBagge
@ny_lars
Thanks for this very important piece of evidence. Awaiting OS results of KEYNOTE-054
1
0
5
@TeresaSAmaral
@BeckiLee
@myESMO
Typical question from reimbursing agencies: DMFS reduction is - ~10% at 3 yrs, but ~15% gr. 3-4 TRAE + chronic endocrinopathies, why reimburse the drug in the absence of OS data, even for stage III KN-054 (enrollment completed in 2016, +7 years min. follow up as of today)?
0
0
5
@OncoAlert
@Tony_Calles
@ajsfurness
@bozovicspa
@APassaroMD
@carlos
@Alfdoc2
@BenWestphalen
@weoncologists
@TeresaSAmaral
@darioT_
@DrGomezRoca
@g_mountzios
Capital Region of Denmark: ban to all conferences and meetings
0
1
5
Investigational
#Immunotherapy
at
#ESMO23
:
(minor) tumor regressions after infusion of a personalized, neo-antigen-specific T cell product in patients with
#melanoma
resistant to anti-PD-1
@myESMO
#melsm
#celltherapy
0
1
6
This is a very important platform to develop improved cellular therapies and to test next-gen immuno combos
#Immunotherapy
#ImmunoOncology
Online now: the Voest group at
@NKI_nl
show that co-culturing
#patient
#blood
-derived immune cells with
#tumor
#organoids
can be used to enrich tumor-reactive T cells & assess sensitivity of tumors to
#immunotherapy
ex vivo.
0
53
81
0
0
5
Analysis of common CT scans could be used to select patients for
#immunotherapy
#oncology
#radiomics
New Article online: on a
#radiomics
approach to assess tumour-infiltrating
#CD8
#Tcells
and response to anti-PD-1 or anti-PD-L1
#immunotherapy
: a
#biomarker
study
0
20
25
1
0
5
Particle air pollution and how it works
Presidential Symposium data at
#ESMO22
show air pollution drive interleukin-1β release in cells with EGFR mutations to promote
#LungCancer
development in non-smokers
👉
#LCSM
@TonyMok9
@CharlesSwanton
1
26
55
1
1
5
"Different subclasses of immune environment influence tumor initiation and response to therapy"
0
0
4
Do you have a genuine interest for
#innovation
and a background in
#bioinformatics
,
#DataScience
,
#biology
,
#computerscience
or equivalent? New opportunity to join our
#research
team, to disrupt current paradigms in cancer
#immunotherapy
. If you are interested, please contact me!
New
#research
position available in
@DoniaMarco
's team at
@CCITdk
. If you are a bioinformatician with interest in
#immunotherapy
and
#rnaseq
, do not hesitate to apply! PhD required
#joboffer
#sciencejobs
#bioinformatics
#postdoc
0
7
11
0
3
5
Investigational
#Immunotherapy
at
#ESMO23
:
✅Clinical Responses in HLA-A2+ patients with diverse solid tumor types after infusion of a TCR gene-engineered T cell product
🔴 Serious tox
@myESMO
#celltherapy
0
1
5
Great honour to speak today at the
@Nordic2022
to Nordic dermatologists about modern therapies for
#Melanoma
0
3
15
0
0
4
@OlofssonBagge
@myESMO
Should correct "unprecedented responses to a systemic therapy". Thanks you
@OlofssonBagge
1
0
4
#IOCPH18
to boost
#networking
and
#collaboration
in
#DK
#immunotherapy
hosted by COBIS in collaboration with
@DCCCcancer
Registration is open! Workshop "Public-Private Partnerships in
#immunooncology
" on November 5th, 13:15-20:00 (including dinner) in Copenhagen. Free participation, networking dinner. Register at , in collaboration with
@DCCCcancer
and COBIS
#IOCPH18
0
1
9
0
0
4
Upd 26/6:
DK *no*
SE *no*
NO *no*
PL *negotiating*
NZ *no*
AU *no*
IT *YES*
IR *negotiating*
NL *negotiating*
2
0
4
THE ILLUSION OF EVIDENCE BASED MEDICINE. Worth reading from
@bmj_latest
, but important to avoid misinterpretation:
#EBM
still better than "HCQ+AZT cured my cousin's friend from
#COVID19
". By far
0
0
4
@ivanpantic1980
@TeresaSAmaral
@BeckiLee
Interesting hypothesis-generating, but the observed effect sizes leading to (barely) statistically significant differences are unlikely to hold in a larger study - here
low sample size, 45% incomplete data, more variables to adjust needed. NADINA trial will provide better info
0
1
4
@HeManJespersen
@BettinaRyll
Agree
@HeManJespersen
. We have always known that adjuvant will have inevitably resulted in unnecessary overtreatment of some patients (who would not have relapsed) - with unfortunately, unnecessary side effects
2
0
3
Surgery first or
#Immunotherapy
before surgery in
#melanoma
? Discussed in this issue of
@NatureMedicine
Our November issue is now online! Check out the table of contents here:
0
1
8
0
0
2
1
0
2
@jonsson_lab
@CCITdk
@nanostringtech
@JenWargoMD
@nature
@medfak_LU
@Cancerfonden
@Vetenskapsradet
@lunduniversity
Congratulations
@jonsson_lab
, amazing to work with you!
0
0
3
@darioT_
Thank you
@darioT_
, we indeed recommend large agencies to request
#RWE
data when assessing the real benefit of a novel intervention. Individual smaller agencies, regional or national, may not have sufficient impact on
#BigPharma
to obtain such data on a global scale
0
0
3